Company`s presentation
Licenses and certificates
Download the price-list

Аllercetin rino spray

Аllercetin rino spray

International Nonproprietary Name:

Naphazoline nitrate, diphenhydramine hydrochloride

Pharmaceutical form:

Nasal spray
  • Properties

    Pharmacokinetics

    The therapeutic effect of Allercetin Rino appears 5 -10 minutes after the instillation of the drug and lasts up to 5-6 hours, the effect duration can be reduced up to 4 hours with frequent use of the drug. Active substances of the drug Allercetin Rino, when administered locally, can be absorbed into the systemic blood circulation and exert a resorptive effect.

     

    Pharmacodynamics

    Allercetin Rino is a combination drug for local use containing naphazoline and diphenhydramine. Has antiallergic and vasoconstrictive effect.

    Naphazoline when administrated internasally eases nasal congestion in rhinitis. It promotes opening and expansion of paranasal sinuses paths and clears blocked Eustachian tubes. It simulates secretion discharge and prevents the deposition of bacteria on the nasal mucosa. 

    Diphenhydramine is a blocker of H1-histamine receptors. Has expressed antihistamine activity. Reduces or prevents histamine-induced spasms of smooth muscles, increased capillary permeability, swelling of the tissues, itching and flushing.  It also has a local anesthetic effect, relaxes smooth musculature as a result of direct spasmolytic influence, blocks to a moderate extent the cholinergic receptors of vegetative ganglia.

  • Indications

    • acute rhinitis;

    • allergic rhinosinusitis;

    • allergic vasomotor rhinitis.

    • upper respiratory mucosal hyperemia and swelling after surgery;

    • rhinoscopy facilitation

    .  

  • Contraindications

    • increased sensitivity to the components of the drug;

    • angle closure glaucome;

    • severe eye diseases;

    • arterial hypertension, tachycardia, severe atherosclerosis;

    • hyperthyroidism;

    • diabetes;

    • chronic rhinitis;

    • hypertrophy of the prostate;

    • simultaneous reception of monoamine oxidase inhibitors and a period of up to 14 days after the end of their application;

    • children under 2 years old.

  • Dosage and Administration

    Adults use 0.06% dose: one spray in each nostril three times a day.

    For children:

    • 2 - 6 years: 0.03 dose: one spray in each nostril 1-2 times a day;

    • 6 - 15 years: 0.03% dose: one spray in each nostril three times a day.

    Therapy regimen is 1 week maximum.10 ml in polypropylene (plastic) bottles with a spray cap and protective cap

  • Drug form
    10 ml in polypropylene (plastic) bottles with a spray cap and protective cap